SCHEMBL5398763

SCHEMBL5398763

CCc1nc(OC)c(NC(=O)N2CCN(c3cc(C)cc(C)c3)CC2)cc1C(=O)Nc1cc(CO)cc(Nc2c3ccccc3nc3ccccc23)c1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 8/20 0.42
TOP2B Q02880 8/20 0.42
HTR1A P08908 2/20 0.38
HTR1D P28221 2/20 0.38
HTR1B P28222 2/20 0.38
P2RY12 Q9H244 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
TRPV1 Q8NER1 2/20 0.36
KDM1A O60341 3/20 0.36
ADRA2A P08913 2/20 0.36
ADRA2B P18089 2/20 0.36
ADRA2C P18825 2/20 0.36
MAPT P10636 2/20 0.35
MAPK1 P28482 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5391006 0.95 TOP2A (0.44) TOP2ATOP2BHTR1AHTR1DHTR1B
SCHEMBL5393960 0.94 TOP2A (0.43) TOP2ATOP2BHTR1AHTR1DHTR1B
SCHEMBL5440036 0.93 TOP2A (0.41) TOP2ATOP2BHTR1AHTR1DHTR1B
SCHEMBL5401707 0.93 TOP2A (0.42) TOP2ATOP2BHTR1AHTR1DHTR1B
SCHEMBL5401644 0.93 TOP2A (0.42) TOP2ATOP2BHTR1AHTR1DHTR1B
SCHEMBL5395198 0.92 TOP2A (0.41) TOP2ATOP2BHTR1AHTR1DHTR1B
SCHEMBL5401099 0.91 TOP2A (0.42) TOP2ATOP2BHTR1AHTR1DHTR1B
SCHEMBL5399361 0.90 TOP2A (0.41) TOP2ATOP2BHTR1AHTR1DHTR1B
SCHEMBL5485333 0.87 TOP2A (0.42) TOP2ATOP2BKMT2AMEN1KDM1A
SCHEMBL5435055 0.81 TOP2A (0.38) TOP2ATOP2BKMT2AMEN1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7230105-B2 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2007-06-12 US disclosed
US-20050222167-A1 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2005-10-06 US disclosed
EP-1487799-A4 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARM CO LTD (KR) 2005-06-01 EP disclosed
EP-1487799-A1 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2004-12-22 EP disclosed
WO-2003074490-A1 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222167-A1 9-aminoacridine derivatives and process for the preparation thereof PARP9, CASP9, AMPD2 TOP2A 131/4885TOP2B 209/4885HTR1A 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.